Last updated: September 8, 2026
Desirudin is a recombinant hirudin anticoagulant marketed in the United States as Iprivask for prevention of deep-vein thrombosis after elective hip-replacement surgery. Its commercial opportunity has been limited by a narrow label, parenteral administration, competition from low-molecular-weight heparins and direct oral anticoagulants, and weak visibility into current product availability. Public sources do not provide reliable standalone revenue, prescription, or market-share data for Iprivask. The product’s financial trajectory is therefore best assessed through market structure, regulatory status, competitive substitution, and remaining intellectual-property barriers rather than reported sales.
What is desirudin and what was it approved to treat?
Desirudin is a recombinant form of hirudin, a direct thrombin inhibitor derived from the anticoagulant protein associated with medicinal leech saliva. Iprivask is administered by subcutaneous injection and was approved by the U.S. Food and Drug Administration in 2003 for prophylaxis against deep-vein thrombosis following elective hip-replacement surgery in adults (FDA, 2003).
The approved product is a 15-mg vial for injection. Its clinical use requires reconstitution and administration by injection, with dosing and renal considerations that reduce convenience relative to oral anticoagulants.
Core product attributes
| Attribute |
Desirudin / Iprivask |
| Active ingredient |
Desirudin |
| Drug class |
Direct thrombin inhibitor |
| Product type |
Recombinant peptide biologic |
| U.S. brand |
Iprivask |
| Dosage form |
Injectable vial |
| Approved indication |
DVT prophylaxis after elective hip-replacement surgery |
| U.S. approval |
2003 |
| Administration |
Subcutaneous injection |
| Main clinical risks |
Bleeding, renal accumulation, hypersensitivity |
| Primary commercial substitutes |
Enoxaparin, other LMWHs, fondaparinux, direct oral anticoagulants |
Desirudin is not a biosimilar market in the conventional monoclonal-antibody sense. Any competitor would likely require an abbreviated or full regulatory pathway appropriate to the reference product and dosage form, but the market is more accurately analyzed as a niche injectable anticoagulant market than as a large biologics franchise.
What is the FDA regulatory status of Iprivask?
Iprivask has a U.S. New Drug Application, NDA 021218. FDA labeling identifies desirudin as an anticoagulant for postoperative DVT prevention after hip replacement. The product’s clinical and commercial relevance has declined as orthopedic thromboprophylaxis has shifted toward lower-cost heparins and oral agents.
Public FDA materials should be used to verify current marketing status because drug availability and NDA status can change independently. A product may remain listed in FDA databases while having limited or no active commercial distribution.
FDA milestones
| Date |
Event |
| 2003 |
FDA approval of Iprivask for DVT prophylaxis after elective hip replacement |
| Post-approval period |
Product competed primarily with injectable heparins and later oral anticoagulants |
| Subsequent years |
Commercial availability became limited relative to larger anticoagulant brands |
| Current assessment |
No reliable public evidence supports a material U.S. growth trajectory |
The label does not support broad treatment of venous thromboembolism, atrial fibrillation, acute coronary syndrome, or long-term anticoagulation. That narrow positioning constrains reimbursement, hospital formulary adoption, and sales-force economics.
When does desirudin lose exclusivity?
Desirudin’s meaningful market exclusivity has expired. The original product dates to the early 2000s, and any ordinary small-molecule or formulation patent protection associated with the launch period would generally have reached its statutory term by now unless extended or protected by later patents.
The relevant commercial question is not whether Iprivask retains a durable primary patent moat. It is whether a competitor can economically develop, manufacture, obtain approval for, and distribute a substitutable injectable product in a small market.
Patent-exclusivity assessment
| Protection category |
Desirudin assessment |
| Primary composition protection |
Historical protection; no evidence of a current broad blocking patent of commercial significance |
| Formulation protection |
Potentially relevant to the marketed injectable presentation, but no public evidence indicates a strong current barrier |
| Method-of-use patents |
The approved use is narrow and historically disclosed; durable exclusivity is unlikely |
| Regulatory exclusivity |
Original approval-era exclusivity has expired |
| Orphan exclusivity |
Not applicable based on the approved indication |
| Pediatric exclusivity |
No material current exclusivity identified |
| Patent-term extension |
Any historical extension would not preserve a meaningful current franchise |
| Biosimilar barrier |
Limited practical relevance because the product is a niche recombinant anticoagulant rather than a large biologics platform |
Exact live patent coverage should be confirmed in the USPTO Patent Center and FDA Orange Book before a launch, licensing, or litigation decision. Publicly available commercial signals do not indicate that an active patent estate is supporting substantial pricing power.
What patents protect desirudin formulations and methods of use?
Desirudin protection historically could have covered the recombinant protein, production methods, pharmaceutical compositions, dosage forms, and use in preventing postoperative thrombosis. Those categories are materially different from a current enforceable commercial barrier.
Formulation patents
Formulation claims could cover:
- Stabilized desirudin compositions
- Lyophilized injectable preparations
- Reconstitution systems
- Excipient combinations
- Container-closure systems
- Storage and handling conditions
The commercial value of such patents would depend on whether the claims cover the only practical formulation or merely one presentation. For an injectable peptide with a narrow market, a formulation patent is less valuable if a competitor can use a different excipient system or vial configuration.
Method-of-use patents
Potential method claims could cover administration after hip replacement, dosing schedules, timing relative to surgery, or prevention of thromboembolic events in defined patient populations. Those claims face limited commercial leverage when the approved indication is narrow and competing anticoagulants are already established.
Method-of-use enforcement also depends on the labeling of the competing product. A generic or follow-on manufacturer can reduce risk through non-infringing labeling where the regulatory pathway permits it, although physician prescribing behavior can complicate such strategies.
How strong is the desirudin patent estate?
The current patent estate appears weak from a commercial perspective. The product has no visible high-value platform patent, no broad multi-indication franchise, and no reported patent litigation comparable with major biologic anticoagulants.
Patent strength should be evaluated across five factors:
- Remaining patent term.
- Breadth of composition and formulation claims.
- Ability to design around injectable presentation claims.
- Market value of the protected indication.
- Cost of challenging or avoiding the claims.
Desirudin performs poorly on the fourth factor. Even a technically valid formulation patent would protect a relatively small postoperative market. A competitor could also target the broader anticoagulant market with another active ingredient rather than directly copy desirudin.
What is the Orange Book status of Iprivask?
Iprivask is associated with FDA’s prescription-drug approval framework and should be reviewed in the Orange Book for current active ingredient, dosage form, applicant, and listed patent information. No widely reported, commercially significant Orange Book patent dispute has shaped the U.S. market for Iprivask.
The absence of a visible Paragraph IV litigation record is commercially important. It suggests that the principal barrier to entry is not a contested patent cliff. It is the limited expected return from entering a small and clinically replaceable market.
Paragraph IV challenge risk
A Paragraph IV filing would require a prospective applicant to challenge listed patents or certify that they do not block approval. For desirudin, the likely economics are unfavorable:
- The addressable market is narrow.
- Existing anticoagulants provide strong therapeutic substitutes.
- Injectable manufacturing and quality requirements create costs.
- Hospital purchasing places pressure on price.
- A patent challenge would have limited upside unless the reference product retains a meaningful price premium.
The absence of a public challenge does not establish that no generic or follow-on development is possible. It indicates that the commercial incentive has not been visible.
Which companies compete with desirudin?
Desirudin competes against drug classes rather than against a single direct substitute.
| Competitor class |
Examples |
Competitive advantage |
| Low-molecular-weight heparins |
Enoxaparin, dalteparin |
Established use, broad availability, low cost |
| Factor Xa inhibitors |
Rivaroxaban, apixaban |
Oral dosing and broader use |
| Fondaparinux |
Fondaparinux |
Once-daily injectable dosing and established prophylaxis use |
| Unfractionated heparin |
Heparin |
Low acquisition cost and hospital familiarity |
| Mechanical prophylaxis |
Compression devices |
Avoids pharmacologic bleeding risk in selected patients |
Enoxaparin is the most direct historical commercial comparator in postoperative orthopedic prophylaxis. Direct oral anticoagulants have increased competitive pressure by eliminating injections in appropriate patients. Product selection depends on renal function, bleeding risk, surgical practice, institutional protocols, cost, and regulatory labeling.
How has the desirudin market changed?
The market has shifted from a specialist injectable anticoagulant opportunity toward a low-growth, substitution-exposed niche.
Market dynamics
Desirudin’s original market case depended on a clinical need for reliable postoperative anticoagulation and direct thrombin inhibition. That case weakened as hospitals gained access to inexpensive LMWH products and oral factor Xa inhibitors.
The product also lacks the commercial characteristics associated with durable biologic growth:
- No broad chronic-use indication
- No major outpatient disease market
- No high-frequency specialty prescribing
- No strong patient-administered convenience profile
- No large expansion into atrial fibrillation or venous thromboembolism treatment
- No disclosed platform or lifecycle program
Hospital procurement further reduces pricing power. A formulary committee can substitute another anticoagulant without requiring a new diagnostic workflow or specialized administration infrastructure.
What is the financial trajectory of desirudin?
No reliable public source provides standalone current revenue for desirudin or Iprivask. The available evidence supports a trajectory of initial specialty-market commercialization followed by stagnation, limited availability, and commercial decline.
Financial trajectory
| Period |
Commercial interpretation |
| Launch and early adoption |
Specialty product positioned for postoperative DVT prevention |
| Expansion period |
Limited opportunity because the label remained narrow |
| Competitive maturity |
Pressure from LMWHs, generic anticoagulants, and oral factor Xa inhibitors |
| Late commercial period |
Lower visibility, restricted distribution, and reduced strategic value |
| Current outlook |
Low-growth or non-material revenue opportunity without a new indication or manufacturing relaunch |
Desirudin is unlikely to represent material revenue exposure for a diversified pharmaceutical company. Its value would be higher in a targeted acquisition of injectable anticoagulant assets only if the buyer has an existing hospital portfolio, manufacturing capacity, or a plan to expand the product into a broader indication.
A relaunch would face several financial hurdles:
- Revalidation or transfer of manufacturing
- Sterile injectable quality controls
- Limited formulary demand
- Price competition from generic anticoagulants
- Medical-affairs spending to change prescribing behavior
- Potential need for new clinical studies for an expanded label
What generic launch scenarios exist for desirudin?
Three launch scenarios are plausible.
Scenario 1: No direct generic entry
This is the most commercially rational scenario if the market remains small and the reference product has limited availability. Competitors can serve the clinical need with established alternatives without reproducing desirudin.
Scenario 2: Low-price injectable entrant
A manufacturer with existing sterile injectable capacity could enter with a lower-priced desirudin product if regulatory requirements and reference-product availability are manageable. This would likely erode price rapidly and leave limited room for multiple suppliers.
Scenario 3: Lifecycle reformulation or expanded indication
A sponsor could seek value through a prefilled syringe, improved stability, or a new indication. The cost and clinical-development burden would be difficult to justify against established oral anticoagulants unless the product demonstrated a clear safety or efficacy advantage.
What licensing deals and litigation affect desirudin?
No major recent licensing transaction, settlement agreement, or patent litigation involving desirudin is widely reported as a driver of market value. Historical commercialization involved corporate changes and product-rights activity, but public disclosure has not established a current transaction structure capable of supporting a meaningful revenue forecast.
The lack of visible litigation is consistent with a low-value patent estate and limited generic-entry incentive. It does not indicate that the product has no regulatory or manufacturing risks.
How does desirudin compare with other anticoagulants?
| Factor |
Desirudin |
Enoxaparin |
Rivaroxaban or apixaban |
| Administration |
Injection |
Injection |
Oral |
| Clinical positioning |
Narrow postoperative prophylaxis |
Broad hospital and postoperative use |
Broad outpatient and chronic use |
| Generic competition |
Limited visibility |
Strong |
Increasing |
| Manufacturing complexity |
Sterile recombinant injectable |
Sterile injectable |
Oral solid dosage |
| Pricing power |
Low |
Low to moderate by setting |
Historically higher, declining with competition |
| Market size |
Niche |
Large |
Large |
| Lifecycle potential |
Limited |
Moderate |
High relative to desirudin |
Desirudin’s principal disadvantage is strategic scope. Competing products can be used across more patient groups, indications, and care settings.
Key Takeaways
- Desirudin, marketed as Iprivask, is a recombinant direct thrombin inhibitor approved for DVT prophylaxis after elective hip replacement.
- Its commercial market is narrow and has been pressured by LMWHs, generic anticoagulants, and oral factor Xa inhibitors.
- Original regulatory exclusivity and historical patent protection no longer provide a visible durable moat.
- No major current Paragraph IV dispute, settlement, or patent litigation is publicly associated with the product.
- Standalone revenue and market-share data are not reliably disclosed.
- The financial trajectory is consistent with a niche product that moved from specialty commercialization to limited or declining commercial relevance.
- A new entrant would face more risk from market size, sterile manufacturing, and formulary substitution than from a strong blocking patent estate.
- The product has low strategic value unless paired with manufacturing infrastructure, a hospital portfolio, or a credible lifecycle plan.
Frequently Asked Questions
Is desirudin still commercially available in the United States?
Public availability has been limited and should be verified against current FDA and distributor records. FDA approval and commercial distribution are separate issues.
Is desirudin a biosimilar?
Desirudin is a recombinant biologic peptide, but it is not part of the large monoclonal-antibody biosimilar market. Its commercial market is closer to a niche injectable anticoagulant market.
Can a generic manufacturer challenge Iprivask patents?
A manufacturer could pursue an applicable abbreviated regulatory pathway and make the required patent certifications. The limited market reduces the economic incentive for a Paragraph IV challenge.
Does desirudin have a broad anticoagulant label?
No. The U.S. label is centered on prevention of DVT after elective hip-replacement surgery. It is not a broad chronic anticoagulation product.
What is the main investment risk for a desirudin asset?
The main risk is insufficient market demand. Manufacturing, reimbursement, and competitive substitution are more significant commercial concerns than a visible, long-duration patent barrier.
References
-
U.S. Food and Drug Administration. (2003). Iprivask (desirudin) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Iprivask application information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Approved drug product list and patent information. FDA.
-
National Library of Medicine. (n.d.). DailyMed: Desirudin drug labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
